Sealy Institute for Vaccine Sciences (SIVS) has been redesignated a PAHO/WHO
(Pan American Health Organization/World Health Organization)
Collaborating Center (WHO CC) for Vaccine Research, Evaluation and
Training on Emerging Infectious Diseases. Dr. Alan Barrett continues as the
WHO Collaborating Centers
support WHO to investigate public health issues from many angles,
ranging from basic science and animal studies to clinical trials, public
policy, training and funding. UTMB is clearly recognized as one of the most important
international leaders in the vaccine development world, therefore, the world experts on vaccine development at UTMB received an international designation acknowledging their unique
niche in a sphere where research, government regulation and big pharma
UTMB’s Sealy Center for Vaccine Development (now designated the Sealy Institute for Vaccine Sciences) was named a World
Health Organization Collaborating Center (WHO CC) for Vaccine Research,
Evaluation and Training on Emerging Infectious Diseases. The designation
by the World Health Organization
(WHO) makes UTMB only the second university in the Western Hemisphere
to receive this designation; the other is the Johns Hopkins Bloomberg
School of Public Health, Baltimore, MD. UTMB is also only the seventh university in the world to
receive WHO designation for vaccine expertise. In addition to the Johns
Hopkins Bloomberg School of Public Health, the others are the University
of Geneva in Switzerland; University of Zurich in Germany; University of Lausanne in
Switzerland; the Second Military Medical University in Shanghai, China; and the
University of Antwerp in Belgium.
The terms of reference of the WHO CC are:
- To track progress and provide analysis of the vaccine pipeline against emerging infectious diseases.
- To conduct research on the development, evaluation and use of vaccines against emerging infectious diseases of public health importance.
- To provide education and training for future investigators in the field of vaccinology.